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Researchers around the world join forces to reconstruct the molecular processes of the virus-
host interactions aiming to combat the cause of the ongoing pandemic.
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We announce the COVID-19 Disease Map (https://doi.org/10.17881/covid19-disease-map), an effort to build a comprehensive, standardized knowledge repository of SARS-CoV-2 virus-host interaction mechanisms, guided by input from domain experts and based on published work. This knowledge, 
available in the vast body of existing literature1,2 and the fast-growing number of new SARS-CoV-2 publications, 
needs rigorous and efficient organization in both human and machine-readable formats.
This endeavour is an open collaboration between clinical researchers, life scientists, pathway curators, com-
putational biologists and data scientists. Currently, 162 contributors from 25 countries around the world are 
participating in the project, including partners from Reactome3, WikiPathways4, IMEx Consortium5, Pathway 
Commons6, DisGeNET7, ELIXIR8, and the Disease Maps Community9. With this effort, we aim for long-term 
community-based development of high-quality models and knowledge bases, linked to data repositories.
The COVID-19 Disease Map will be a platform for visual exploration and computational analyses of molec-
ular processes involved in SARS-CoV-2 entry, replication, and host-pathogen interactions, as well as immune 
response, host cell recovery and repair mechanisms. The map will support the research community and improve 
our understanding of this disease to facilitate the development of efficient diagnostics and therapies. Figure 1 
illustrates the initial scope and layout of the map and its life cycle.
At the time this Comment went to press, the COVID-19 Disease Map contains pathways of (i) the virus 
replication cycle and its transcription mechanisms; (ii) SARS-CoV-2 impact on ACE2-regulated pulmonary 
blood pressure, apoptosis, Cul2-mediated ubiquitination, heme catabolism, Interferon 2 and PAMP signalling, 
and endoplasmic reticulum stress; (iii) SARS-CoV-2 proteins Nsp4, Nsp6, Nsp14 and Orf3a. Moreover, the map 
incorporates the COVID-19 collection of WikiPathway diagrams10 and a pre-published genome-scale metabolic 
model of human alveolar macrophages with SARS-CoV-211. All these contributed open-access resources are ref-
erenced at https://fairdomhub.org/projects/190#models.
By combining diagrammatic representation of COVID-19 mechanisms with underlying models, the map 
fulfils a dual role. First, it is a graphical, interactive representation of disease-relevant molecular mechanisms 
linking different knowledge bases. Second, it is a computational resource of reviewed content for graph-based 
analyses12 and disease modelling13. Thus, it provides a platform for domain experts, such as clinicians, virologists, 
and immunologists, to collaborate with data scientists and computational biologists for a rigorous model build-
ing, accurate data interpretation and drug repositioning. It offers a shared mental map to understand gender, age, 
and other susceptibility features of the host, disease progression, defence mechanisms, and response to treatment. 
Finally, it can be used together with the maps of other human diseases to study comorbidities.
In the construction of the COVID-19 Disease Map, we rely on multiple tools for curation and review the 
contributed content in a distributed, on-the-fly manner. Most importantly, already at this early stage, we involve 
practising physicians and clinical researchers to improve the scope and quality of the map. Motivated by our cura-
tion experience and the number of participants contributing to the construction of the map, we propose and reg-
ularly revise common curation guidelines and follow commonly-accepted exchange standards. Moreover, given 
Fig. 1 The overview of the COVID-19 Disease Map project. The map focuses on SARS-CoV-2 replication cycle, 
its interactions with the host, reaction of the immune system and repair mechanisms. The curated and reviewed 
content will be continuously integrated and cross-linked with data and knowledge bases, to support visual and 
computational exploration, as well as disease modelling efforts. The acquired results will benefit the research 
community and provide feedback to refine the scope of curation activities.
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the multicellular and multiorgan nature of COVID-19 infection and the complexity of the underlying molecular 
mechanisms, we envisage the map as a hierarchical structure of interconnected functional modules. We anticipate 
that the structure of the map will evolve as new knowledge about the disease is revealed.
This distributed, multi-tool, multi-group approach is dictated by the urgency of the ongoing pandemic, by 
the high volume of new COVID-19-related publications, and by an impressive response from the research com-
munity. In this challenging situation, it is imperative that community-based approaches are used to develop 
high-quality models and data. To ensure a transparent view of the contributors and community resources, we rely 
on the support of FAIRDOMHub14. All data and curation guidelines related to the COVID-19 Disease Map are 
available at https://fairdomhub.org/projects/190.
We invite curators to join the project and contribute to building a solid foundation of COVID-19 molecu-
lar and cellular mechanisms using systems biology standards15–17. Moreover, we request support from domain 
experts to advise on the content and to review the map, improving its quality and applicability, as well as experts 
in modelling to accelerate the development of efficient diagnoses, treatments, and vaccines in response to the 
ongoing pandemic.
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